Phase 4
N=180
Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty
Total Knee Arthroplasty
Bottom Line
View on ClinicalTrials.gov: NCT02798835 ↗Enrolled (actual)
180
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Cumulative 24 Hour Oral Morphine Equivalent Consumption — 111.8; 118; 153 mg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Adductor canal block (Drug); Adductor canal block with dexamethasone (Drug); Adductor canal catheter (Drug); Bupivacaine (Drug); Fentanyl (Drug); Ropivacaine 0.5% Injectable Solution (Drug); Dexamethasone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of British Columbia
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative 24 Hour Oral Morphine Equivalent Consumption |
111.8; 118; 153 | — |
| SECONDARY Cumulative 12 Hour Oral Morphine Equivalent Consumption |
61.5; 49.5; 82 | — |
| SECONDARY Cumulative 48 Hour Oral Morphine Equivalent Consumption |
192.9; 196; 223.5 | — |
| SECONDARY Pain Score |
3; 3; 4; 3; 3; 3 | — |
| SECONDARY Quality of Recovery (QoR-40) |
160.5; 166.5; 167.2 | — |
| SECONDARY Length of Stay |
70.8; 71.5; 71.5 | — |
| SECONDARY Incidence of Participants With Nausea/Vomiting Requiring Anti-emetics |
19; 14; 19; 26; 17; 24 | — |
| SECONDARY Time to First Use of PCA |
4.1; 4.9; 3.8 | — |
Summary
This study investigates single injection adductor canal block (ACB) with or without intravenous dexamethasone and adductor canal catheter for pain management of total knee arthroplasty. This is a non-inferiority trial seeking to determine whether single injection ACB with dexamethasone is "no worse" than a continuous catheter.
Eligibility Criteria
Inclusion Criteria
- Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent
- Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3
- Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents
- Patients must be able to understand and be able to use patient controlled analgesia
- Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia
Exclusion Criteria
- Patients with a contraindication to neuraxial and/or regional anaesthesia
- Patients with an allergy to local anaesthetics
- Patients who have chronic pain not related to their knee joint
- Patients with chronic opioid use (daily or almost daily use >3 months)
- Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)
- Patients with pre-existing neuropathy
- Patients with hepatic failure
- Patients with renal failure with eGFR<60
- Patients with allergy to ketorolac or NSAIDs
Data sourced from ClinicalTrials.gov (NCT02798835). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.